Physician profile
Perry Jay Olson
NPI 1104847847
$882.95
in general payments reported to CMS, 2019-2025
16 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $16.04 · 2023: $246 · 2024: $484 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $866.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $160.40 | 2023-2024 | Ozempic, Rybelsus |
| Abbvie INC. | $115.58 | 2023-2024 | |
| Pfizer INC. | $102.66 | 2023-2025 | |
| Exact Sciences Corporation | $67.19 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $63.86 | 2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $56.58 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.06 | 2024-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $52.55 | 2024-2025 | Flumist Quadrivalent, Airsupra, Breztri |
| Alkermes, INC. | $48.20 | 2023-2024 | Vivitrol, Vivitrol |
| Glaxosmithkline, LLC. | $39.34 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Boston Scientific Corporation | $24.92 | 2024 | Wavewriter Alpha Prime 16 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.49 | 2024 | Jardiance |
| Axsome Therapeutics, INC. | $21.33 | 2025 | Auvelity |
| Astellas Pharma US INC | $18.60 | 2023 | Myrbetriq |
| Phathom Pharmaceuticals, INC. | $18.15 | 2024 | Voquezna |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $16.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Perry Olson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.